Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study

BACKGROUND: In the 52-week ETHOS study (NCT02465567), fixed-dose triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) reduced moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations versus fixed-dose long-acting muscarinic antagonist (LAMA)/long-act...

Descripción completa

Detalles Bibliográficos
Autores principales: de Nigris, Enrico, Treharne, Catrin, Brighton, Nick, Holmgren, Ulf, Walker, Andrew, Haughney, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700475/
https://www.ncbi.nlm.nih.gov/pubmed/36444374
http://dx.doi.org/10.2147/COPD.S381138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700475/
https://www.ncbi.nlm.nih.gov/pubmed/36444374
http://dx.doi.org/10.2147/COPD.S381138

Ejemplares similares